Valerio Maria Rosaria, Martorana Federica, Sanò Maria Vita, Sambataro Daniela, Motta Gianmarco, Motta Lucia, Pavone Giuliana, Gebbia Vittorio, Scandurra Giuseppa
Medical Oncology Unit, Policlinico Paolo Giaccone, University of Palermo, 90133 Palermo, Italy.
Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
Biomedicines. 2025 Feb 21;13(3):546. doi: 10.3390/biomedicines13030546.
Adherence to oral anticancer therapies among breast cancer patients is an often-overlooked issue. A lack of patient compliance can be caused by several factors, and may hinder the efficacy of prescribed medication, leading to a shorter than expected survival. In this context, few data about adherence to CDK4/6 inhibitors in real-world practice are available. We report here the results of a retrospective analysis of adherence to abemaciclib plus endocrine therapy in a cohort of women with hormone receptor-positive (HR+), epidermal growth factor 2 negative (HER2-) breast cancer. Abemaciclib adherence was computed as the ratio between the total number of cycles/months that medication was supplied and the months between the first and the last prescription. The proportion of Days Covered (PDC) ranged from 0 to 1. A score of 0.8 (i.e., 80% adherence rate) was the cutoff used to classify the patients as adherent (0.8 ≤ PDC ≤ 1) or non-adherent (0 ≤ PDC < 0.8). The received dose intensity was also calculated. The abemaciclib pharmacy claims of 100 women with HR+/HER2- breast cancer were retrieved. Most patients (91%) were treated in the advanced setting. Abemaciclib was more frequently taken with an aromatase inhibitor (63%) than with fulvestrant (27%). In this population, the adherence rate was high (92.25% + 1.939 SD). The proportion of non-adherent patients taking abemaciclib with PDC <0.8 was 12%. There was a significative correlation between the occurrence of side effects and the use of <5 drugs for non-oncological illnesses, probably reflecting concomitant non-oncological diseases. Adherence to abemaciclib-based therapy is high in a real-life setting, pending the adequate and proactive management of patients. The careful evaluation of patients and detailed information about expected adverse events are essential to ensure adherence to this antineoplastic agent.
乳腺癌患者对口服抗癌疗法的依从性是一个常被忽视的问题。患者依从性差可能由多种因素引起，并可能阻碍处方药的疗效，导致生存期短于预期。在此背景下，关于在实际临床中对CDK4/6抑制剂的依从性数据很少。我们在此报告了一项对一组激素受体阳性（HR+）、表皮生长因子2阴性（HER2-）乳腺癌女性患者使用阿贝西利联合内分泌治疗的依从性进行回顾性分析的结果。阿贝西利的依从性通过药物供应的总周期数/月数与首次和最后一次处方之间的月数之比来计算。覆盖天数比例（PDC）范围为0至1。以0.8分（即80%的依从率）作为将患者分类为依从（0.8≤PDC≤1）或不依从（0≤PDC<0.8）的临界值。还计算了接受的剂量强度。检索了100名HR+/HER2-乳腺癌女性患者的阿贝西利药房申领记录。大多数患者（91%）接受晚期治疗。与氟维司群（27%）相比，阿贝西利更常与芳香化酶抑制剂（63%）联合使用。在该人群中，依从率较高（92.25%+1.939标准差）。PDC<0.8的服用阿贝西利的不依从患者比例为12%。副作用的发生与非肿瘤性疾病使用<5种药物之间存在显著相关性，这可能反映了合并的非肿瘤性疾病。在现实生活中，对基于阿贝西利的治疗的依从性较高，但需要对患者进行充分且积极的管理。对患者进行仔细评估以及提供有关预期不良事件的详细信息对于确保对这种抗肿瘤药物的依从性至关重要。
